Bimekizumab
Common brands: Bimzelx, Methotrexate, Vitamin D, Cosentyx, Rasuvo
Top reporter: Ucb, Inc.
Nonsteroidal Anti-inflammatory Drug [EPC]Corticosteroid [EPC]Interleukin-17A Antagonist [EPC]GLP-1 Receptor Agonist [EPC]Provitamin D2 Compound [EPC]
16,071
Total Reports
13,341
Serious Reports
116
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.72%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Bimekizumab.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PRODUCT DOSE OMISSION ISSUE | 2,604 | |
| 2 | PSORIASIS | 2,019 | |
| 3 | DRUG INEFFECTIVE | 1,487 | |
| 4 | PSORIATIC ARTHROPATHY | 1,391 | |
| 5 | OFF LABEL USE | 1,202 | |
| 6 | HIDRADENITIS | 1,191 | |
| 7 | INJECTION SITE PAIN | 960 | |
| 8 | CONDITION AGGRAVATED | 911 | |
| 9 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 766 | |
| 10 | THERAPY INTERRUPTED | 735 | |
| 11 | PRODUCT AVAILABILITY ISSUE | 704 | |
| 12 | INCORRECT DOSE ADMINISTERED | 571 | |
| 13 | PAIN | 568 | |
| 14 | ORAL CANDIDIASIS | 559 | |
| 15 | FATIGUE | 532 | |
| 16 | PRURITUS | 502 | |
| 17 | HEADACHE | 477 | |
| 18 | RASH | 415 | |
| 19 | INSURANCE ISSUE | 390 | |
| 20 | DIARRHOEA | 346 | |
| 21 | CANDIDA INFECTION | 344 | |
| 22 | ARTHRALGIA | 335 | |
| 23 | NO ADVERSE EVENT | 296 | |
| 24 | DEVICE ISSUE | 295 | |
| 25 | ADVERSE DRUG REACTION | 293 | |
| 26 | THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 291 | |
| 27 | ANKYLOSING SPONDYLITIS | 285 | |
| 28 | NASOPHARYNGITIS | 282 | |
| 29 | ILLNESS | 281 | |
| 30 | DEPRESSION | 280 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.